Replies to post #2441 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

If EDP-235 advances to phase-3, ENTA will likely seek to show non-inferiority to Paxlovid, which ought to be an achievable goal.

There is no FDA requirement that a COVID drug has to show any particular result for viral load or IVA to get approval.